• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 mRNA 的 CAR T 细胞通过微型化两步电穿孔制造,对靶癌细胞具有选择性细胞毒性。

mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells.

机构信息

Department of Electrical and Computer Engineering, North Dakota State University, Fargo, North Dakota, USA.

Biomedical Engineering Program, North Dakota State University, Fargo, North Dakota, USA.

出版信息

Lab Chip. 2021 Sep 28;21(19):3748-3761. doi: 10.1039/d1lc00219h.

DOI:10.1039/d1lc00219h
PMID:34585697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8513750/
Abstract

There is a growing interest for viral vector-free chimeric antigen receptor (CAR) T-cells due to its ability to kill cancer cells without adverse side effects. A potential avenue for manufacturing viral-vector free CAR T-cells is to utilize mRNA electroporation. One of the major concerns with mRNA electroporated CAR T-cells is the shorter cytotoxic lifespan of a few days, which is insufficient or not ideal for therapy. To better understand this issue and develop a potential solution, this study focused on examining the translation of electroporated mRNA to CAR molecules, time dependent degradation of CAR molecules and cytotoxicity produced by CAR T-cells on cancer cells. It was found that the initial expression of CAR molecules dictates the cytotoxicity. Initial CAR expression could be controlled by the experimental parameters such as electroporation time and mRNA concentration in the electroporation buffer. Experiments were carried out using a novel two-step electroporation that allows for controlled and uniform transfection of T-cells. These technical advancements and subsequent findings could provide a viable path for producing CAR T-cells with longer cytotoxic lifespans.

摘要

由于其能够在没有不良反应的情况下杀死癌细胞,因此人们对无病毒载体嵌合抗原受体 (CAR) T 细胞越来越感兴趣。制造无病毒载体 CAR T 细胞的一种潜在方法是利用 mRNA 电穿孔。mRNA 电穿孔 CAR T 细胞的一个主要问题是其细胞毒性寿命较短,仅有几天,这对于治疗来说是不够的或不理想的。为了更好地理解这个问题并开发潜在的解决方案,本研究专注于研究电穿孔 mRNA 到 CAR 分子的翻译、CAR 分子的时间依赖性降解以及 CAR T 细胞对癌细胞的细胞毒性。结果发现,CAR 分子的初始表达决定了细胞毒性。初始 CAR 表达可以通过实验参数来控制,如电穿孔时间和电穿孔缓冲液中的 mRNA 浓度。实验使用了一种新的两步电穿孔方法,可实现 T 细胞的受控和均匀转染。这些技术进步和随后的发现为生产具有更长细胞毒性寿命的 CAR T 细胞提供了可行的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/39a1ea75ea99/nihms-1734827-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/8878be2c0f7e/nihms-1734827-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/61e9425c1933/nihms-1734827-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/1514dbc477fe/nihms-1734827-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/046d387d27bd/nihms-1734827-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/d768da8ab2df/nihms-1734827-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/975f063ac3a2/nihms-1734827-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/632314aacb8e/nihms-1734827-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/f35d420c2e1c/nihms-1734827-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/39a1ea75ea99/nihms-1734827-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/8878be2c0f7e/nihms-1734827-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/61e9425c1933/nihms-1734827-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/1514dbc477fe/nihms-1734827-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/046d387d27bd/nihms-1734827-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/d768da8ab2df/nihms-1734827-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/975f063ac3a2/nihms-1734827-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/632314aacb8e/nihms-1734827-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/f35d420c2e1c/nihms-1734827-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b58/8513750/39a1ea75ea99/nihms-1734827-f0010.jpg

相似文献

1
mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells.基于 mRNA 的 CAR T 细胞通过微型化两步电穿孔制造,对靶癌细胞具有选择性细胞毒性。
Lab Chip. 2021 Sep 28;21(19):3748-3761. doi: 10.1039/d1lc00219h.
2
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.多次注射表达嵌合抗原受体的电穿孔自体 T 细胞可介导人转移性肿瘤消退。
Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.
3
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.用嵌合抗原受体或 α/β T 细胞受体对 γ/δ T 细胞进行 RNA 转染:用于黑色素瘤免疫治疗的基因工程化 α/β T 细胞的更安全替代方法。
BMC Cancer. 2017 Aug 17;17(1):551. doi: 10.1186/s12885-017-3539-3.
4
The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.单独或同时下调 PD-1 和 CTLA-4 的 siRNA 可增强体外 CAR-T 细胞的功能,从而进一步开发用于黑色素瘤免疫治疗的潜在用途。
Exp Dermatol. 2018 Jul;27(7):769-778. doi: 10.1111/exd.13678.
5
Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured electroporation or lentiviral transfection.电穿孔或慢病毒转染制造的嵌合抗原受体 T 淋巴细胞的表型和转录组特征的差异。
Front Immunol. 2023 May 9;14:1068625. doi: 10.3389/fimmu.2023.1068625. eCollection 2023.
6
In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.体外转录(IVT)-mRNA嵌合抗原受体疗法的开发。
Methods Mol Biol. 2020;2086:87-117. doi: 10.1007/978-1-0716-0146-4_7.
7
Treatment of advanced leukemia in mice with mRNA engineered T cells.用 mRNA 工程化 T 细胞治疗小鼠晚期白血病。
Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.
8
Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.嵌合抗原受体T细胞工艺开发中的生物材料
Acc Chem Res. 2020 Sep 15;53(9):1724-1738. doi: 10.1021/acs.accounts.0c00335. Epub 2020 Aug 6.
9
In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.体外转录信使 RNA 嵌合抗原受体 T 细胞(IVT mRNA CAR T)疗法在血液系统恶性肿瘤和实体瘤治疗中的临床前进展。
Int J Mol Sci. 2020 Sep 6;21(18):6514. doi: 10.3390/ijms21186514.
10
Automating CAR-T Transfection with Micro and Nano-Technologies.利用微纳技术实现 CAR-T 转染自动化
Small Methods. 2024 Aug;8(8):e2301300. doi: 10.1002/smtd.202301300. Epub 2023 Dec 6.

引用本文的文献

1
The Pre-Polarization and Concentration of Cells near Micro-Electrodes Using AC Electric Fields Enhances the Electrical Cell Lysis in a Sessile Drop.利用交流电场对微电极附近细胞进行预极化和浓缩可增强静态液滴中的电穿孔细胞裂解。
Biosensors (Basel). 2025 Jan 6;15(1):22. doi: 10.3390/bios15010022.
2
Synthetic circRNA therapeutics: innovations, strategies, and future horizons.合成环状RNA疗法:创新、策略与未来展望。
MedComm (2020). 2024 Nov 9;5(11):e720. doi: 10.1002/mco2.720. eCollection 2024 Nov.
3
Efficient electroporation in primary cells with PEDOT:PSS electrodes.利用聚(3,4-乙烯二氧噻吩):聚苯乙烯磺酸盐电极实现原代细胞的高效电穿孔。
Sci Adv. 2024 Oct 25;10(43):eado5042. doi: 10.1126/sciadv.ado5042.
4
Beyond Conventional Treatments: Exploring CAR-T Cell Therapy for Cancer Stem Cell Eradication.超越传统疗法:探索 CAR-T 细胞疗法根除癌症干细胞。
Stem Cell Rev Rep. 2024 Nov;20(8):2001-2015. doi: 10.1007/s12015-024-10786-4. Epub 2024 Sep 23.
5
Analysis of In Situ Electroporation Utilizing Induced Electric Field at a Wireless Janus Microelectrode.利用无线双面微电极处的感应电场对原位电穿孔进行分析。
Micromachines (Basel). 2024 Jun 25;15(7):819. doi: 10.3390/mi15070819.
6
Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.开发一种微流控细胞转染装置,将其纳入基因编辑 CAR T 细胞制造工作流程中。
Lab Chip. 2023 Nov 7;23(22):4804-4820. doi: 10.1039/d3lc00311f.
7
Cancer immunotherapies: advances and bottlenecks.癌症免疫疗法:进展与瓶颈。
Front Immunol. 2023 Aug 24;14:1212476. doi: 10.3389/fimmu.2023.1212476. eCollection 2023.
8
Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.靶向 CD7 CAR T 细胞治疗 T 淋巴细胞白血病和淋巴瘤及急性髓系白血病:最新进展。
Front Immunol. 2023 May 5;14:1170968. doi: 10.3389/fimmu.2023.1170968. eCollection 2023.
9
Tumor buster - where will the CAR-T cell therapy 'missile' go?肿瘤克星——CAR-T 细胞疗法的“导弹”将飞向何方?
Mol Cancer. 2022 Oct 19;21(1):201. doi: 10.1186/s12943-022-01669-8.
10
Recent Advances in Microscale Electroporation.微尺度电穿孔技术的最新进展
Chem Rev. 2022 Jul 13;122(13):11247-11286. doi: 10.1021/acs.chemrev.1c00677. Epub 2022 Jun 23.

本文引用的文献

1
Acoustophoretic rapid media exchange and continuous-flow electrotransfection of primary human T cells for applications in automated cellular therapy manufacturing.声电泳快速介质交换和原代人 T 细胞的连续流电转染在自动化细胞治疗生产中的应用。
Lab Chip. 2019 Sep 10;19(18):2978-2992. doi: 10.1039/c9lc00458k.
2
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function.用于嵌合抗原受体T细胞抗肿瘤功能预测评估的体外肿瘤细胞再激发
J Vis Exp. 2019 Feb 27(144). doi: 10.3791/59275.
3
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.RNA 修饰的 T 细胞介导免疫调节细胞因子向脑肿瘤的有效递送。
Mol Ther. 2019 Apr 10;27(4):837-849. doi: 10.1016/j.ymthe.2018.10.007. Epub 2018 Oct 17.
4
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.免疫疗法:替沙格赛定 - 首个获批的嵌合抗原受体T细胞疗法:对支付方和政策制定者的影响
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.
5
Global Manufacturing of CAR T Cell Therapy.嵌合抗原受体T细胞疗法的全球生产
Mol Ther Methods Clin Dev. 2016 Dec 31;4:92-101. doi: 10.1016/j.omtm.2016.12.006. eCollection 2017 Mar 17.
6
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.嵌合抗原受体(CAR)T细胞:B细胞恶性肿瘤中靶向CD19的经验教训。
Drugs. 2017 Mar;77(3):237-245. doi: 10.1007/s40265-017-0690-8.
7
Controllable in-situ cell electroporation with cell positioning and impedance monitoring using micro electrode array.使用微电极阵列进行可控的原位细胞电穿孔,同时进行细胞定位和阻抗监测。
Sci Rep. 2016 Aug 10;6:31392. doi: 10.1038/srep31392.
8
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.间皮素特异性嵌合抗原受体 mRNA 修饰 T 细胞在实体恶性肿瘤中诱导抗肿瘤活性。
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
9
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
10
ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.ApoStream(™),一种新的介电泳设备,用于在血液中实现抗体独立分离和回收活的癌细胞。
Biomicrofluidics. 2012 Jun 27;6(2):24133. doi: 10.1063/1.4731647. Print 2012 Jun.